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Abstract
Background: Regulatory T cells (Tregs) are highly prevalent in tumor tissue and can suppress effective anti-tumor immune
responses. However, the source of the increased tumor-infiltrating Tregs and their contribution to cancer progression
remain poorly understood.
Methodology/Principal Finding: We here investigated the frequency, phenotype and trafficking property of Tregs and their
prognostic value in patients with hepatocellular carcinoma (HCC). Our results showed that FoxP3
+ Tregs highly aggregated
and were in an activated phenotype (CD69
+HLA-DR
high) in the tumor site, where they can suppress the proliferation and
INF-c secretion of CD4
+CD25
2 T cells. These tumor-infiltrating Tregs could be selectively recruited though CCR6-CCL20 axis
as illustrated by (a) high expression of CCR6 on circulating Tregs and their selective migration to CCR6 ligand CCL20, and (b)
correlation of distribution and expression between tumor-infiltrating Tregs and intratumoral CCL20. In addition, we found
that the number of tumor-infiltrating Tregs was associated with cirrhosis background (P=0.011) and tumor differentiation
(P=0.003), and was an independent prognostic factor for overall survival (HR=2.408, P=0.013) and disease-free survival
(HR=2.204, P=0.041). The increased tumor-infiltrating Tregs predicted poorer prognosis in HCC patients.
Conclusions: The CCL20-CCR6 axis mediates the migration of circulating Tregs into tumor microenvironment, which in turn
results in tumor progression and poor prognosis in HCC patients. Thus, blocking CCL20-CCR6 axis-mediated Treg migration
may be a novel therapeutic target for HCC.
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Introduction
Regulatory T cells (Tregs) are a subgroup of CD4
+ T cells
characterized by expression of CD25 and a key transcription
factor, known as forkhead box P3 (FoxP3) [1]. They can suppress
the activation, proliferation and effector functions of various
immune cells in vitro and in vivo [2]. This unique ability makes
Tregs central in the prevention of autoimmune disease and
maintenance of allograft tolerance. However, as a double-edged
sword, Tregs can also suppress anti-cancer immune responses and
favor tumor progression [3]. Thus, the relation of Tregs to
carcinogenesis has become a field of intense investigation recently.
Emerging evidences demonstrate Tregs also play a central role
in the immunopathogenesis of cancers [4]. First, a higher
frequency of Tregs in both peripheral blood and tumors was
reported in patients with a variety of cancers [4]. This list
continues to grow following the current interest of studying Tregs
in human tumors. Second, the number of tumor-infiltrating Tregs
is negatively associated with patient prognosis [5,6]. Third, it has
been established that in murine models, selective depletion of
Tregs can induce regression of established tumors [1,7]. Overall,
Treg-cell-mediated immunosuppression is one of the crucial tumor
immune-evasion mechanisms and the main obstacle of successful
tumor immunotherapy [1,8,9].
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide [10] with a poor prognosis and limited survival
in the majority of patients. Nowadays, Tregs are being extensively
studied in human HCC. Increased number of Tregs has been
reported in peripheral blood and, particularly, tumor tissues of
patients with HCC [11,12,13,14]. Furthermore, the main
mechanisms by which Tregs facilitate liver carcinogenesis are to
prevent CD8
+ T cells from proliferating in response to tumor-
associated antigens and from becoming cytotoxic effector cells
[12,13,14]. However, little is known about the mechanisms leading
to the increased Tregs in tumor tissue. It is summarized that there
are four mechanisms responsible for this, and the recruitment of
Tregs is the most important approach [1].
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procedure, in which signals from chemokines/chemokine recep-
tors play a critical role [15]. The migratory capacity of Tregs is
controlled by distinct signals from chemokines/chemokine recep-
tors [4]. The following chemokine receptors have been reported
on Tregs: CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CXCR3,
and CXCR4 [4,16,17,18]. In human ovarian and breast cancers,
the CCL22/CCR4 signal has been demonstrated to mediate this
procedure [5,19]. However, the migratory determinants for Treg-
cell migration into tumor tissues of HCC patients remain
unknown. In this study, we found that the CCR6-CCL20 axis
determines the migration of circulating Tregs into tumor tissues in
HCC patients.
Results
CD4
+CD25
+FoxP3
+ Tregs are highly enriched in tumors of
HCC patients
We initially investigated whether Tregs accumulate in tumors of
HCC patients. The prevalence of Tregs was identified by flow
cytometry after cell surface labeling of CD4 and CD25 molecules.
As expected, the frequency of CD4
+CD25
+ T cells in tumor-
infiltrating lymphocyte (TIL), representing 34.962.7% of CD4
+ T
cells, was significantly higher than those in non-tumor-infiltrating
lymphocyte (NIL; 7.860.6%), and peripheral blood mononuclear
cells from HCC patients (cPBMC; 16.761.2%), HBV patients
(vPBMC; 11.761.3%) and healthy donors (nPBMC; 6.760.7%)
(P,0.001, Figure 1a, b). Additionally, the frequency of circulating
CD4
+CD25
+ T cells was also higher in HCC patients compared
with healthy donors (P,0.001).
To determine quantity and distribution of Tregs in tumor tissue,
we performed immunohistochemical staining of FoxP3 in paraffin-
embedded tissue from HCC patients (Group 1, n=293).
Consistent with the flow cytometric analysis, we observed that
FoxP3
+ cells preferentially accumulated in tumor tissue (7.360.6/
hpf) rather than in non-tumor tissue (2.860.4/hpf) or normal
control livers (0.460.1/hpf) (both P,0.001 for T vs. nT and T vs.
NC; Figure 2c, d). Importantly, the distribution of FoxP3
+ cells in
tumor region differed from that in non-tumor region. In tumor
tissue, most of FoxP3
+ cells locate in the parenchymal region,
where the FoxP3
+ cells are close to liver tumor cells, while in non-
tumor tissue, the majority of FoxP3
+ cells aggregate in the
mesenchymal region (parenchyma: mesenchyma, 7:5 in tumor vs.
5:22 in non-tumor, P,0.001; Figure 1e). These results suggest that
Tregs are highly enriched in tumor tissue, and that physical
contact between Tregs and tumor cells may be necessary to
mediate regulatory functions [11].
Phenotypic and functional analysis of CD4
+CD25
+ Tregs
in HCC patients
CD4
+CD25
+ T cells, whatever their origin, highly expressed
FoxP3, cytolytic T lymphocyte-associated antigen 4 protein
(CTLA-4) and CD45RO, three specific markers constitutively
expressed by classic Tregs (Figure 2a) [20]. However, the mean
fluorescence intensity (MFI) of FoxP3 in CD4
+CD25
+ T cells from
TIL was higher than those from NIL, cPBMC, and nPBMC
(P,0.05, Figure 2b). Importantly, most CD4
+CD25
+ Tregs from
TIL and NIL exhibited an activated memory phenotype
(CD69
+HLA-DR
+), with the highest CD69 and HLA-DR
expression on TIL-derived CD4
+CD25
+ Tregs (Figure 2a). We
also found that CD4
+CD25
+ T cells from TIL, NIL, or cPBMC
similarly inhibited the proliferation and INF-c production of
autologous CD4
+CD25
2 T cells (Tconv) in a dose-independent
manner (n=3, P,0.05; Figure 2c). These data indicated that
CD4
+CD25
+ T cells from tumor tissue of HCC have an activated
phenotype and immunosuppressive property.
Increased CCL20, secreted by liver tumor cells, is
associated with the number of tumor-infiltrating Tregs
To identify what chemokine mediates the recruitment of tumor-
infiltrating Tregs, we investigated the selective chemokines in
tumor and non-tumor regions by real-time PCR. These
chemokines are ligands of CCR2, CCR4, CCR5, CCR6,
CCR7, CCR8, CXCR3, and CXCR4, all of which have been
reported to be expressed on Tregs [21]. We found that only the
mRNA expression of CCL20 was significantly increased in tumor
than in non-tumor and normal control tissues (T vs. nT, P,0.001;
T vs. NC, P=0.021; Figure 3a). For the other chemokines, their
mRNA expression was lower in tumor than in non-tumor region
(Figure 3a). Notably, the expression of CCL19, CCL21, CXCL9,
and CXCL12 was significantly decreased (P,0.05).
Next, we detected the CCL20 expression at the protein level by
immunohistochemical to verify the results of PCR, and to clarify
the source of CCL20. Consistent with real-time PCR, the CCL20
expression in tumor tissue was significantly stronger than that in
non-tumor (integrated optical density/hpf, 14529 vs. 4969,
P,0.001) and normal liver tissue (vs. 1534, P=0.001) (Figure 3b,
c). We observed large amounts of CCL20-secreting cancer cells
and, occasionally, scattered CCL20-secreting Kuffer cells in tumor
region (Figure 3b, right). However, in non-tumor region, CCL20 is
secreted mainly by Kuffer cells (Figure 3b, middle) [22]. These
results collectively indicate that CCL20, rather than other
chemokines, mediates the trafficking of Tregs into tumor tissue;
and that liver tumor cells are major sources of CCL20 in tumor
microenvironment.
Furthermore, we evaluated the relationship of Tregs to CCL20
in the same tumor environment by immunohistochemistry. First, a
strongly positive correlation was observed between the number of
FoxP3
+ Tregs and CCL20 expression in tumor tissue (P,0.001;
Figure 3d, left), but not in non-tumor tissue (P=0.894; Figure 3d,
right). Next, we performed immunohistochemical double-staining
of FoxP3 and CCL20 to visualize the mutual distributions of Tregs
and CCL20. As shown, FoxP3
+ cells mainly assemble in the sites
where CCL20 is highly expressed (Figure 3e, left). Meanwhile, we
observed the attraction of tumor cells to FoxP3
+ cells by secreting
massive CCL20 (Figure 3e, right). These results indicate that, to
some extent, the amount of tumor-secreted CCL20 determines the
prevalence of Tregs in the same site.
Circulating CD4
+CD25
+ Tregs in HCC patients highly
express CCR6, and selectively migrate to tumors under
recruitment of CCL20
To reveal whether the expression of CCR6, the exclusive
receptor of CCL20, on circulating Tregs was increased corre-
spondingly, we analyzed the expression of CCR6 on CD4
+ T-cell
subsets by flow cytometry. We found cPBMC-derived
CD4
+CD25
+ Tregs expressed significantly higher CCR6
(7062%, n=29) than autologous CD4
+CD25
2 T cells or Tregs
from the other groups (P,0.01 or 0.001, Figure 4a, b). Different
from CCR6 expression, the frequency of CCR4 on cPBMC-
derived Tregs (4063%, n=20) was lower than that on nPBMC-
derived counterparts (5563%, n=12; P,0.001), though higher
than that on autologous CD4
+CD25
2 T cells (1562%, P,0.001)
(Figure 4a). CCR7 was similarly expressed on both CD4
+CD25
+
and CD4
+CD25
2 T cells from blood or tissue (Figure 4a).
Altogether, these observations suggest that Tregs in peripheral
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CCR6.
Next, we detected the chemotaxis of cPBMC-derived
CD4
+CD25
+ T cells to CCL20 in vitro. Significant chemotacitc
responses to recombinant human CCL20 were observed in
cPBMC-derived CD4
+CD25
+ T cells than in autologous
CD4
+CD25
2 T cells and cPBMC-derived counterparts (n=3,
P,0.01, Figure 4c). Further, a neutralizing monoclonal antibody
to CCL20 did markedly blocked CCL20-induced migration of
cPBMC-derived CD4
+CD25
+ T cells (P,0.001, Figure 4c). In
contrast to CCL20, both CCL22 and CCL21 (specific ligands for
CCR4 and CCR7, respectively) only induced weak migration of
cPBMC-derived CD4
+CD25
+ T cells. SMMC-7721, a human
HCC cell line, was detected to highly secrete CCL20 by real-time
PCR and enzyme-linked immunosorbent assay (data not shown).
The chemotactic effect of SMMC-7721 supernatant was also
tested on cPBMC-derived CD4
+CD25
+ T cells. Like CCL20,
SMMC-7721 supernatant induced significant migration of
cPBMC-derived CD4
+CD25
+ T cells (P,0.01 versus control),
which can be efficiently blocked by antibody to CCL20, but not by
antibody to CCL22 or CCL21 (Figure 4c). Thus, CCL20 mediates
Tregs trafficking in vitro and may recruit Tregs into the tumor.
Furthermore, we investigated the expression of integrins LFA-1
(CD11a) and aEb7 (CD103), and L-selectin (CD62L) on Tregs,
since the combination of selecins, integrins and chemokine
receptors is responsible for the selective migration of Tregs
[23,24]. We found that nearly all CD4
+CD25
+ T cells expressed
CD11a (.98%, Figure 5a), a dominant integrin involved in
lymphocyte arrest [25]. Importantly, the intensity of CD11a on
TIL-derived CD4
+CD25
+ T cells (MFI, 74556805) was signifi-
cantly stronger than those on cPBMC- (41446229) or nPBMC-
derived counterparts (34806364) (P,0.05, Figure 5b), suggesting
that CD11a might be helpful to Treg migration. The expression of
CD62L, essential molecular for homing to lymph node [4], was
strongly reduced in TIL-derived Tregs compared with patient
blood Tregs (P,0.01, Figure 5a, c), while that of CD103, critical
to skin-specific homing [21], was extremely low in all studied
groups (,25%; Figure 5a, d). Thus, we consider that neither
CD103 nor CD62L might be related to liver-specific migration of
Tregs.
Treg prevalence is associated with tumor progression
and predicts poor survival of HCC patients
Finally, we assessed the association of tumoral FoxP3
+ Tregs
with clinical characteristics. Using the median number of FoxP3
+
Tregs determined by immunohistochemical staining (6.6 cells/hpf)
as the cutoff, patients were divided into two groups: High (n=148)
and Low Treg groups (n=145). We found that increased tumor
FoxP3
+ cells were correlated with the presence of cirrhosis
(P=0.011) and poorer tumor differentiation (P=0.003) (Table 1),
indicating that the accumulation of these cells is associated with
disease progression. In that case, we further predicted whether
tumor Tregs would adversely affect survival. To test this
prediction, we analyzed all relevant clinical and pathological
information, including the number of tumor Tregs, with tumor-
associated survival on 143 patients with follow-up evaluation.
There was a significant inverse correlation of tumor Treg density
with both overall survival (median survival time, 28 months in
High vs. 48 months in Low, P=0.024) and disease-free survival
(median survival time, 22 months in High vs. 47 months in Low,
Figure 1. CD4
+CD25
+FoxP3
+ Tregs are highly enriched in tumors of HCC patients. Tregs (CD4
+CD25
+ T cells) were gated from CD3
+ T cells
by flow cytometry. (a, b) Representative plots (a) and statistical analysis (b) show that the frequency of CD4
+CD25
+ T cells was higher in HCC patients,
especially among TIL. The percentages in (a) represent the frequency of CD4
+CD25
+ T cells among CD4
+ T cells. The data in (b) are expressed in box
plots, in which the horizontal lines illustrate the 25th, 50th and 75th percentiles. (c, d) Representative images (c) and statistical analysis (d) of
immunohistochemical staining of FoxP3
+ lymphocytes in the tumor and non-tumor tissue from HCC patient and normal control liver. Magnification,
6200. The data in (d) show that the number of FoxP3
+ cells is significantly higher in tumor than in non-tumor or normal control. hpf, high-powered
field. (e) Statistical analysis shows FoxP3
+ cells preferentially aggregate in the parenchyma of tumors.
doi:10.1371/journal.pone.0024671.g001
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+
Treg density was found to be an independent prognostic factor of
overall survival (Hazard Ratio, 2.4; P=0.013) and disease-free
survival (Hazard Ratio, 2.0; P=0.041) (Table 2). These results
show that the prevalence of tumor FoxP3
+ Tregs can serve as an
independent predictor of poor prognosis for HCC patients.
Discussion
In this study, we show that the presence of tumor-infiltrating
CD4
+CD25
+ T cells are typical Tregs based on their
CD4
+CD25
+FoxP3
highCD45RO
+CTLA-4
+ phenotype and suppres-
sive functions. We also found that FoxP3
+ Tregs were concentrated
within HCC tumors, and that the intratumoral prevalence of FoxP3
+
Tregs was associated with disease progression and poor prognosis.
More importantly, we revealed that the CCL20-CCR6 axis controls
the migration of circulating Tregs into tumor, resulting in the
increased frequency and quantity of Tregs in tumor tissue.
It is reported that CD4
+CD25
+ T cells (Tregs) constitute 5–10%
of peripheral CD4
+ T cells in healthy people [1,26]. Consistent
with these reports, the CD4
+CD25
+ T cells counted for 6.760.7%
of CD4
+ T cells in healthy donor based on our gating strategy.
Importantly, we observed a substantial increase of tumor-
infiltrating CD4
+CD25
+ Tregs in both frequency and quantity,
in agreement with previous findings [11,13,27]. FoxP3 is a master
regulator of Tregs for their development, maintenance and
function [28]. Here, we found that the level of FoxP3 was higher
in tumor-derived Tregs. However, Tregs from HCC patients
showed similar immunosuppressive effects, as CD4
+CD25
+ T cells
from either TIL, NIL or cPBMC similarly inhibited the
proliferation and INF-c production of autologous CD4
+CD25
2
T cells. These data suggested that the prevalence, rather than the
Figure 2. Phenotypic and functional analysis of CD4
+CD25
+ Tregs in HCC patients. (a) Representative FoxP3, CTLA-4, CD45RO, CD69 and
HLA-DR expression profiles in CD4
+CD25
+ (thick line) and CD4
+CD25
2 (dotted line) T cells from the four studied groups. Specific isotypes were used
as negative control. The percentages represent the frequencies of various markers on CD4
+CD25
+ T cells. The italic numerical values represent MFI of
FoxP3 in CD4
+CD25
+ T cells. (b) Statistical analysis shows that the MFI of FoxP3 in CD4
+CD25
+ T cells from TIL was significantly higher than those from
NIL, cPBMC, and nPBMC. *P,0.05, compared with TIL. (c) Purified CD4
+CD25
+ T cells (Tregs) from TIL, NIL, and cPBMC could similarly inhibit the
proliferation and INF-c production of autologous CD4
+CD25
2 T cells (Tconv) in a dose-dependent manner (n=3 for each group). *P,0.05; **P,0.01,
compared with autologous controls (Treg:Tconv=0:1). Data in (b) and (c) represent the mean6S.E.M.
doi:10.1371/journal.pone.0024671.g002
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ment results in reduced tumor-specific immunity [1]. In addition,
we showed that, in contrast to paired blood Tregs, tumor-
infiltrating Tregs display an activated phenotype, as they expressed
elevated levels of CD69 and HLA-DR. Only ,30% of Tregs
expressed low level of HLA-DR in patient peripheral blood, while
the majority of tumor-derived Tregs highly expressed HLA-DR,
which identifies a terminally differentiated subpopulation of
effector Tregs [3]. Therefore, this means that most of Tregs are
terminally differentiated ones in tumor microenvironment.
The high number of tumor-infiltrating in the liver tumor
environment raises the question of their recruitment. Over the past
decade, CCR4 and its ligands have been demonstrated to play
critical role in recruiting circulating Tregs into tumor tissue.
Circulating Tregs have been revealed to express high CCR4 levels
and to selectively migrate in response to CCR4 ligands produced
in the tumor microenvironment [5,19,29,30]. However, we
observed that, in HCC patients, circulating Tregs highly express
CCR6 and migrate to CCL20 present in the tumor microenvi-
ronment. This conclusion is based on two findings. First, only the
Figure 3. Increased CCL20, secreted by liver tumor cells, is associated with the number of tumor-infiltrating Tregs. (a) Real-time PCR
of selective chemokines in tumor and non-tumor regions of HCC patients and in normal control liver. The value was normalized to GAPDH, multiplied
by 10
5, and log transformed. (b) immunohistochemical staining of chemokine CCL20 (brown, cytoplasm). Numerous CCL20-secreting tumor cells are
seen in tumor region, and a few CCL20-secreting Kuffer cells in non-tumor region. Magnification, 6200; insert boxes, 6400. (c) Statistical analysis
shows the CCL20 level in tumor tissue is significantly stronger than that in non-tumor and normal liver tissues. IOD, integrated optical density. (d) The
correlations between CCL20 level and the number of FoxP3
+ cells in tumor (left) and non-tumor (right) regions. The expression of CCL20 and FoxP3
were detected by immunohistochemical staining, and quantified as described in ‘‘Materials and Methods’’. (e) Double staining of CCL20 (red,
cytoplasm) and FoxP3 (brown, nucleus). The regions expressing high and low levels of CCL20 are marked by ‘‘w’’ and‘‘*’’, respectively. Big arrows
indicate CCL20-secreting tumor cells, and small arrows FoxP3
+ cells. Magnification, 6200, left; 6400, right.
doi:10.1371/journal.pone.0024671.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24671Figure 4. Circulating CD4
+CD25
+ Tregs in HCC patients highly express CCR6, and selectively migrate to tumors under recruitment
of CCL20. (a) Representative plots of CCR6, CCR4 and CCR7 on CD4
+CD25
+ (solid line) and CD4
+CD25
2 (dotted line) T cells from different
compartments. Specific isotypes were used as negative control. The percentages represent frequencies of CCR6, CCR4 and CCR7 on CD4
+CD25
+ T
cells. (b) Statistical analysis shows that cPBMC-derived CD4
+CD25
+ Tregs expressed significantly higher CCR6 than autologous CD4
+CD25
2 T cells or
Tregs from the other groups. **P,0.01, ***P,0.001. (c) CD4
+CD25
+ T cells migrate in response to recombinant human CCL20 or supernatant of
SMMC-7721 cells (n=3). A specific antibody to CCL20 significantly inhibits CD4
+CD25
+ T cell migration. Data represent the mean6S.E.M. **P,0.01,
***P,0.001.
doi:10.1371/journal.pone.0024671.g004
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protein levels in tumor tissues. Moreover, the CCL20 expression
was strong correlated with the number of FoxP3
+ Tregs in tumor
environment. Second, the circulating Tregs from HCC patients
highly expressed CCR6, and selectively migrate in response to
CCL20 in vitro. It is worth noting that the Tregs in tumor
environment expressed low to even undetectable CCR6. We infer
this may result from the strong expression of CCL20 in tumor
environment, which inversely internalizes the CCR6 expression
like CCR4 [19]. In the past, CCR6 was mainly implicated to be
responsible for the inflammatory recruitment of Tregs. Fox
example, CCR6 is essential for the optimal recruitment of Tregs
to sites of Th17-mediated inflammation in experimental autoim-
mune encephalomyelitis (EAE) [31]. However, recently, accumu-
lating finding show that the CCR6 expression on Tregs also plays
a critical role in tumor development [32,33]. It is well accepted
that not only the suppressor potential but also appropriate
localization determines the in vivo suppressive capacity of Tregs
[34]. All these results, together with our data, show an important
role of CCR6 in Treg-mediated immunosuppression.
Although they are critical factors to mediate Treg migration
into tumors or lymph nodes, CCR4 and CCR7 are at least not
essential for migration of circulating Tregs from HCC patients in
this study. First, none of the ligands for CCR4 and CCR7 had
enhanced expression in tumor environment. Second, although
they had much higher expression of CCR4 than CD4
+CD25
2 T
cells, the circulating Tregs appeared to have significantly lower
frequency of CCR4 than their counterparts in normal controls.
Likewise, the expression of CCR7 between CD4
+ T subsets was
similar and did not fluctuate substantially among groups. Third,
chemotaxis assays failed to show selective migration of circulating
Tregs from HCC patients to CCL22 and CCL21.
Several studies assessed the association of increased tumor-
infiltrating Tregs with clinical characteristics and revealed different
results. Tang et al. found that high tumor Treg density was
associated with both absence of tumor encapsulation and presence
of tumor vascular invasion [6]. Another studies revealed that the
prevalence of Tregs was correlated with the presence of cirrhosis
and later TNM stages [35]. We found that increased tumor
FoxP3
+ Tregs was also correlated with cirrhosis background, but
more importantly with poorer tumor differentiation. Though
somewhat different, all these results mean Tregs contribute to
tumor progression in HCC patients. Meanwhile, elevated tumor-
infiltrating Treg number (.6.6/hpf) also predicted a poorer
prognosis with shorter disease-free and overall survival, in line with
previous reports in liver tumors [6,35].
Figure 5. Differential expression of CD11a, CD62L and CD103 on CD4
+CD25
+ Tregs. (a) Representative CD11a, CD62L, and CD103
expression profiles on CD4
+CD25
+ (solid line) and CD4
+CD25
2 (dotted line) T cells from the four studied groups. Specific isotypes were used as
negative control. The percentages represent the frequencies of various markers on CD4
+CD25
+ T cells. The italic numerical values represent MFI of
CD11a on CD4
+CD25
+ T cells. (b–d) Statistical analyses of CD11a intensity (b), as well as CD62L (c) and CD103 (d) frequencies on CD4
+CD25
+ Tregs.
The data are expressed in box plots, in which the horizontal lines illustrate the 25th, 50th and 75th percentiles. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0024671.g005
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24671In conclusion, we report here the frequency, phenotype, and
trafficking property of Tregs and their correlation with clinica-
pathologic factors in HCC patients. Especially, we found that
CCR6 is a liver-specific determinant for the trafficking of
circulating Tregs into tumor. These results extend our under-
standing of the mechanism of liver carcinogenesis. Thus, apart
from depleting Tregs, blocking Treg-cell trafficking into tumor
represents a potential strategy for treating human HCC.
Methods
Ethics Statement
The study protocol was approved by the Institutional Review
Board of Key Lab of Combined Multi-organ Transplantation,
Ministry of Public Health. Informed written consent was obtained
from patients according to the Declaration of Helsinki.
Subjects
A total of 293 patients with HCC were enrolled in this study.
None of the HCC patients had received immunosuppressive
drugs or chemotherapy. Paraffin-embedded, formalin-fixed liver
sections were obtained from 293 patients (Group 1) who
underwent surgical resection between 2005 and 2010. Of these
patients, 143 patients with follow-up evaluation (Group 2) were
further enrolled in survival analysis. Overall survival was defined
as the interval between the dates of surgery and death, and
Disease-free survival the interval between the dates of surgery and
recurrence or the last follow-up. Matched fresh blood, tumor and
non-tumor (at least 3 cm distant from the tumor tissue) samples
were also obtained from 39 patients (Group 3) with HCC. The
patient characteristics of three groups are described in Table 3.
Liver tissues from 10 donors for living donor liver transplanta-
tion, and fresh blood samples from 14 patients with HBV
infection but without HCC and 30 healthy volunteers were used
as control.
Isolation of peripheral blood mononuclear cells (PBMC),
TIL, and NIL
PBMC were isolated by Ficoll-Hypaque (Sigma-Aldrich, St.
Louis, MO) density gradient separation. TIL and NIL were
isolated as described [27]. Briefly, the tissue was cut into small
pieces and incubated in an enzyme mixture containing 0.05%
collagenase IV (Invitrogen, Carlsbad, CA) and 0.001% DNase I
(Sigma-Aldrich) for 1 h. Dissociated tissues were then ground
through a 70-mm strainer, and mononuclear cells were obtained by
density gradient separation using Ficoll-Hypaque.
Table 1. Correlation between tumor FoxP3
+ cell and
clinicopathologic characteristics.
FoxP3
+ Cells
Characteristics Low High P
No. of Patients 148 145
Age, #50/.50 years 63/85 54/91 0.325
Sex, Male/Femal 128/20 118/27 0.234
HBsAg, Negative/Positive 27/121 31/114 0.501
AFP level, #400/.400 ng/mL 97/51 81/64 0.090
ALT level, #40/.40 U/L 75/73 87/58 0.108
Child-Pugh score, A/B+C 136/12 131/14 0.520
Liver cirrhosis, Yes/No 100/48 77/68 0.011
Tumor size, #5/.5 cm 80/68 75/70 0.690
Tumor encapsulation, None/Presence 117/31 123/22 0.199
Tumor number, Single/Multiple 103/45 102/43 0.889
Vascular invasion, Yes/No 39/109 41/104 0.721
TNM stage, I+II/III+IV 104/44 98/47 0.620
Tumor differentiation, I2II/III 89/59 62/83 0.003
HBsAg, Hepatitis B surface antigen; AFP, a-fetoprotein; ALT, alanine
aminotransferase.
doi:10.1371/journal.pone.0024671.t001
Figure 6. Accumulation of tumor Treg cells predicts poor survival in patients with hepatocellular carcinoma. The cumulative overall
survival and disease-free survival of HCC patients were estimated using the Kaplan-Meier method and compared by the log-rank test. Patients with
high FoxP3
+ Tregs (dashed lines) had significantly poorer survival compared with individuals with low FoxP3
+ Treg density (solid lines).
doi:10.1371/journal.pone.0024671.g006
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PBMC, TIL and NIL were stained with fluorochrome-
conjugated mAbs against human CD3, CD4, CD25, CD45RO,
CD69, HLA-DR, CCR4, CCR6, CCR7, CD11a, CD62L,
CD103, FoxP3, and CTLA-4 (BD PharMingen, San Diego,
CA). For intracellular staining, the cells were permeabilized and
fixed using Cytofix/Cytoperm (BD PharMingen) according to the
manufacturer’s instructions. After staining, three- or four-color
flow cytometry was performed using LSR II flow cytometer
(Becton Dickinson, San Jose, CA), and data were analyzed using
Flowjo software (Tree Star, Inc., Ashland, OR).
Immunohistochemical staining
Paraffin-embedded, formalin-fixed liver tissue was cut into 4-mm
sections. Antigen retrieval was preformed via pressure cooking for
10 minutes in citrate buffer (pH 6.0). Antibodies of mouse anti-
human FoxP3 (dilution, 1:200) and rabbit anti-human CCL20
(dilution, 1:150) (Abcam, Cambridge, UK) were used for the
primary antibodies. Diaminobenzidine is used for substrate
following counterstaining with hematoxylin for single staining.
DoublestainingwaspreformedusingEnVision
TMG|2Doublestain
System (Dako, Glostrup, Denmark) with 2 different Chromogens:
DAB
+ Chromogen (brown color) for FoxP3 and Permanent Red
Chromogen (red color) for CCL20. For quantitative analysis of the
CCL20 staining, the integrated optical density, which represents the
mean optical density multiplied by cell area, was measured by the
Image-Pro Plus 6.0(MediaCybernetics, Baltimore,MD)in10 high-
powered fields as described [36].
Real-time PCR
RNA was extracted using the RNeasy Mini kit (Qiagen, Hilden,
Germany) and synthesized for cDNA using QuantiTech Reverse
Transcription kit (Qiagen). Quantitative real-time PCR was
conducted in SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) using the ABI Prism 7500 Real-time PCR System
(Applied Biosystems). The primer sequences listed in Table 4.
Samples were run in triplicate, and their relative expression was
calculated in the following formula using GAPDH as endogenous
controls: 2
2DDCt.
Immunosuppression Assays
CD4
+CD25
+ (Treg) and CD4
+CD25
2 (Tconv) T cells were
separated from PBMC using magnetic beads (purity, .97%;
Table 3. Characteristic of Patients with HCC.
Group
Variables 1 2 3
No. of patients 293 143 39
Mean age 6 SD, yr 54.3611.2 52.0610.1 53.169.8
Gender, male/female 246/47 125/18 33/5
HBsAg, positive/negative 235/58 120/23 37/2
Background, CH/LC 102/139 30/105 13/26
AFP level (ng/ml), .400/#400 115/178 58/85 11/28
Child-Pugh score, A/B/C 267/24/2 116/25/2 39/0/0
ALT level, .40/#40 U/L 131/162 70/73 17/22
Tumor size
* (cm), .5/#5 138/155 65/78 18/21
Number of tumors, single/multiple 205/88 88/55 7/32
Tumor stage, I/II/III/IV 148/55/83/7 63/32/41/7 20/11/8/0
Tumor differentiation, I/II/III 21/130/142 6/72/65 2/21/16
HBV, hepatitis B virus; HCV, hepatitis C virus; CH, chronic hepatitis; LC, liver
cirrhosis; AFP, alpha-fetoprotein.
*Tumor size is expressed by the maximum diameter of tumors.
doi:10.1371/journal.pone.0024671.t003
Table 2. Univariate and Multivariate analysis of factors associated with survival and recurrence.
Overall survival Disease-free survival
Univariate Multivariate* Univariate Multivariate*
Variables HR P HR P HR P HR P
Age, #50/.50 years 1.287 0.448 0.445 0.012 0.448 0.035
Sex, Male/Femal 2.262 0.129 0.995 0.991
HBsAg, Negative/Positive 0.644 0.269 0.801 0.594
AFP, #400/.400 ng/mL 2.472 0.007 NA 0.061 1.816 0.067 NA 0.650
ALT, #40/.40 U/L 1.501 0.226 1.383 0.317
Child-Pugh score, A/B+C 1.022 0.957 0.682 0.390
Liver cirrhosis, Yes/No 0.712 0.366 0.936 0.858
Tumor size, #5/.5 cm 2.032 0.032 2.246 0.020 1.778 0.067 NA 0.642
Tumor encapsulation, None/Presence 0.036 0.064 NA 0.097 0.096 0.120
Tumor number, Single/Multiple 0.627 0.152 0.462 0.014 NA 0.116
Vascular invasion, Yes/No 2.247 0.013 NA 0.252 2.139 0.018 NA 0.985
TNM stage, I+II/III+IV 1.883 0.052 NA 0.363 4.169 0.000 3.723 0.000
Tumor differentiation, I2II/III 1.760 0.095 NA 0.669 1.983 0.037 NA 0.230
FoxP3, Low/High 2.084 0.027 2.408 0.013 2.204 0.14 2.204 0.041
Univariate and multivariate analysis: Cox proportional hazards regression model.
HR, Hazard Ratio; NA, not adopted.
*Multivariate variables were adopted by univariate analysis (P,0.10).
doi:10.1371/journal.pone.0024671.t002
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+CD25
+ regulatory T cell isolation kit; Miltenyi Biotec).
Purified Tregs (2.5610
4/well) were cultured in triplicate with
autologous purified Tconv from TIL, NIL, or cPBMC in the
presence of 2.5 mg/ml soluble anti-CD3 mAbs (BD PharMingen)
plus 5 mg/ml anti-CD28 mAbs (BD PharMingen). The added
Treg:Tconv ratio was 0:1, 0.5:1, or 1:1. After 4 days, [
3H]
Thymidine (Amersham, Freiburg, Germany) was added for 16 h
(0.5 mCi/well), and then cells were harvested and counted in a
scintillation counter.
Enzyme-linked immunosorbent assay
The concentration of interferon-c (IFN-c) in the culture
supernatants was determined using enzyme-linked immunosorbent
assay kits (eBioscience, San Diego, CA) according to the
manufacturer’s instructions.
Chemotaxis assay
CD4
+CD25
+ and CD4
+CD25
2 T cells were isolated as
described above, while chemotaxis assays were performed as
previously described [5,37]. Briefly, 5610
5 CD4
+CD25
+ or
CD4
+CD25
2 T cells in a volume of 200 ml were added to the
upper wells (insert pore size, 5 mm; Millipore, Billerica, MA).
Human chemokines (CCL20, CCL21 and CCL22, 100 ng/ml of
each; all from R&D System, Minneapolis, MN), or supernatant of
SMMC-7721 cell line (Cell Research Institute of the Chinese
Academy of Sciences, Shanghai, China) were added to the lower
chamber in a volume of 900 ml. After 4 h at 37uC, cells migrating
to the lower chamber were enumerated using a hemocytometer.
The SMMC-7721 tumor cell line was cultured in RPMI-1640
medium supplemented with 10% FCS in a humidified 5% CO2 at
37uC. SMMC-7721 supernatant used for chemotaxis assay was
collected after 3- to 5-day-old culture. Antibodies to CCL20,
CCL21 and CCL22 (R&D System) were added just before the
chemotactic experiments at a saturated concentration of 500 ng/
ml. Chemotactic index represents the ratio of cells migrated in the
presence of CCL20 to the cells migrated spontaneously with
medium alone. Assays were performed as triplicates.
Statistic analysis
All statistical data were analyzed using SPSS, version 16.0.
Differences between groups were analyzed using one-way
ANOVA, Mann-Whitney U test, or x2 test where appropriate.
Pearson coefficient was computed to assess the association between
CCL20 and FoxP3
+ cells in the tumor environments. Cumulative
survival times were calculated by the Kaplan–Meier method and
different survival functions between groups were analyzed by the
log-rank test. A multivariate Cox proportional hazards regression
model was used to identify independent prognostic factors. Data
were expressed as means 6 S.E.M. Statistical significance was set
at P,0.05.
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